ILARIS is an interleukin-1β blocker indicated for the treatment of: 1. Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). 2. Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS). 3. Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD). 4. Familial Mediterranean Fever (FMF). Active Systemic Juvenile Idiopathic Arthritis (SJIA).
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of ILARIS (canakinumab) for injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the ILARIS (canakinumab) for injection medicine cost price in India.
The order for ILARIS (canakinumab) for injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Canakinumab (INN, trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha
ILARIS® (canakinumab) injection, for subcutaneous use Initial U.S. Approval: 2009
Generic Name: canakinumab
For Injection: 150 mg lyophilized powder in single-dose vials for reconstitution.
Injection: 150 mg/mL solution in single-dose vials.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand ILARIS (canakinumab) for injection on prescription and Import License in Patient's Name only.
For overseas patients, ILARIS (canakinumab) for injection can be made available in Send your enquiry to find ILARIS (canakinumab) for injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For ILARIS (canakinumab) for injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
FDA approves expanded indications for Ilaris for three rare diseases For More Details
Canakinumab (Ilaris) Gets FDA Nod for Three Rare Periodic Fever Syndromes For More Details